Andere Sprachen Jasper Therapeutics, Inc.

Aktien

A3E3X1

US4718712023

JSPR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 13.05.2024			% 5 Tage	% 1. Jan.
20,76 ^USD	-2,67 %		-7,49 %	+163,12 %

13.05.	Jasper Therapeutics erweitert Mastzellen-Portfolio und startet Asthma-Studie in Q4	MT
06.05.	JASPER THERAPEUTICS, INC. : Bewertung von HC Wainwright kaufen	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Jasper Therapeutics to Expand Mast Cell Portfolio, Initiates Asthma Study in Q4	13.05.
Jasper Therapeutics : Corporate Presentation May 2024	13.05.
Jasper Therapeutics Announces Briquilimab Development Program in Asthma	13.05.
Jasper Therapeutics to Present at Upcoming Investor Conferences in May	07.05.
Certain Restricted Stock Units of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07.05.
Certain Stock Options of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07.05.
Certain Common Stock of Jasper Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-MAY-2024.	07.05.
Jasper Therapeutics : Corporate Presentation April 2024	16.04.
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	21.03.
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19.03.
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19.03.
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	15.03.
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	15.03.
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04.03.
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04.03.
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	04.03.
Jasper Therapeutics : Corporate Presentation March 2024	04.03.
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	26.02.
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Jasper Therapeutics, Inc.

Aktien

A3E3X1

US4718712023

JSPR

Andere Sprachen

Filter